 Leuven, BE, Boston, MA, US April 6, 2021 7.30 AM CET Oxurion NV Euronext Brussels: OXUR, a biopharmaceutical company developing next generation standard-of-care back of the eye therapies, today announces that is has agreed to a capital commitment of up to 30 Million with Negma Group. 